Abstract: One of the new classes of potential cancer biomarkers are microRNAs. MicroRNAs are non-coding RNAs that suppress the translation of their target mRNAs by binding to the 3’ untranslated region³. On the one hand, melanoma-derived exosomes are discussed as vesicles for degradation of anti-tumor microRNAs. On the other hand, exosomal microRNAs might be active in recipient cells4, e.g., by repressing anti-tumorigenic immune responses. To investigate these possibilities, we profiled the microRNA content of exosomes from melanoma cell lines and plasma of melanoma patients. Informed consent was collected according to guidelines for medical and research ethics.Summary: Cutaneous malignant melanoma is a form of skin cancer that accounts for 65% of skin cancer-related deaths. The incidence increases continuously, and while early detection leads to nearly 100% survival rates, the mortality raises to greater than 80% for patients with advanced disease.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Prediction and comparison of PD-1 receptor occupancy in the tumor after treatment with immune checkpoint inhibitors
Dmitry Shchelokov, Oleg Demin Jr
Antibodies for Coronaviruses
Prediction of target receptor occupancy for ALX148, a CD47 blocker, using mechanistic PK/RO modeling
Elena Vasileva, Oleg Demin Jr
IQC Rejection Rules
Development and evaluation of a monoclonal antibody-based colony blot immunoassay for detection of thermotolerant Campylobacter species
Hongsheng Huang and Beverley Phipps-Todd